As several earlier series and preclinical studies have shown, ALK- and EGFR-driven tumors have an immunosuppressive tumor microenvironment with resistance to programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) inhibitors [109,110]. Here, ALK is linked to neoplasm.